Predictors of timing and patterns of recurrence after curative resection for gastric cancer

Digestive Surgery

Volumn 27, Issue 6, 2011, Pages 481-486

  Eom, Bang Wool ^a   Yoon, Hongman ^a   Ryu, Keun Won ^a   Lee, Jun Ho ^a   Cho, Soo Jeong ^a   Lee, Jong Yeul ^a   Kim, Chan Gyoo ^a   Choi, Il Ju ^a   Lee, Jong Seok ^a   Kook, Myung Cherl ^a   Park, Sook Ryun ^a   Nam, Byung Ho ^a   Kim, Young Woo ^a  

^a National Cancer Center   (South Korea)

Author keywords

Gastric cancer; Predictive factor; Recurrence patterns

Indexed keywords

ARTICLE; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; METASTASIS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PERITONEUM TUMOR; STOMACH TUMOR; TIME; TUMOR EMBOLISM; TUMOR RECURRENCE;

FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC CELLS, CIRCULATING; PERITONEAL NEOPLASMS; STOMACH NEOPLASMS; TIME FACTORS;

EID: 78049455776     PISSN: 02534886     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320691     Document Type: Article

References (28)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Department of Population tendency of Korea National Statistical Office: Mortality and the cause of death in 2007. Seoul, Korea National Statistical Office, 2008.
3. Lee SE, Ryu KW, Nam BH, Lee JH, Choi IJ, Kook MC, Park SR, Kim YW: Prognostic significance of intraoperatively estimated surgical stage in curatively resected gastric cancer patients. J Am Coll Surg 2009; 209: 461-467.
4. Schwarz RE, Zagala-Nevarez K: Recurrence patterns after radical gastrectomy for gastric cancer: prognostic factors and implication for postoperative adjuvant therapy. Ann Surg Oncol 2002; 9: 394-400.
5. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS: Recurrence following curative resection for gastric carcinoma. Br J Surg 2000; 87: 236-242 .
6. Wu CW, Lo SS, Shen KH, Hsieh MC, Chen JH, Chiang JH, Lin HJ, Li AF, Lui WY: Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World J Surg 2003; 27: 153-158.
7. Marrelli D, Roviello F, de Manzoni G, Morgagni P, Di Leo A, Saragoni L, De Stefano A, Folli S, Cordiano C, Pinto E, Italian Research Group for Gastric Cancer: Different patterns of recurrence in gastric cancer depending on Lauren's histological type: longitudinal study. World J Surg 2002; 26: 1160-1165.
8. Huang KH, Chen JH, Wu CW, Lo SS, Hsieh MC, Li AF, Lui WY: Factors affecting recurrence in node-negative advanced gastric cancer. J Gastroenterol Hepatol 2009; 24: 1522-1526.
9. Adachi Y, Oshiro T, Mori M, Maehara Y, Sugimachi K: Prediction of early and late recurrence after curative resection for gastric carcinoma. Cancer 1996; 77: 2445-2448.
10. Shiraishi N, Inomata M, Osawa N, Yasuda K, Adachi Y, Kitano S: Early and late recurrence after gastrectomy for gastric carcinoma: univariate and multivariate analyses. Cancer 2000; 89: 255-261.
11. Otsuji E, Kobayashi S, Okamoto K, Hagiwara A, Yamagishi H: Is timing of death from tumor recurrence predictable after curative resection for gastric cancer? World J Surg 2001; 25: 1373-1376.
12. Sakar B, Karagol H, Gumus M, Basaran M, Kaytan E, Argon A, Ustuner Z, Bavbek SE, Bugra D, Aykan FN: Timing of death from tumor recurrence after curative gastrectomy for gastric cancer. Am J Clin Oncol 2004; 27: 205-209.
13. Japanese Gastric Cancer Association: Japanese Classification of Gastric Carcinoma, 2nd English edition. Gastric Cancer 1998; 1: 10-24.
14. Sobin LH, Wittekind C (eds): TNM Classification of Malignant Tumours, ed 6 (UICC). New York, Wiley, 2002.
15. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I, Meyer S, Plukker JT, Van Elk P, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H, Dutch Gastric Cancer Group: Extended lymph node dissection for gastric cancer. N Engl J Med 1999; 340: 908-914.
16. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, Sydes M, Fayers P: Patient survival after D1 and D2 dissection for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer 1999; 79: 1522-1530.
17. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K, ACTS-GC Group: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820.
18. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
19. Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, Cascinu S, Barni S, Labianca R, Torri V: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomized trials. Ann Oncol 2000; 11: 837-843.
20. Liu TS, Wang Y, Chen SY, Sun YH: An updated meta-analysis of adjuvant chemotherapy after curative resection for gastric cancer. Eur J Surg Oncol 2008; 34: 1208-1216.
21. Park JM, Kim YH: Current approaches to gastric cancer in Korea. Gastrointest Cancer Res 2008; 2: 137-144.
22. Hur H, Song KY, Park CH, Jeon HM: Followup strategy after curative resection of gastric cancer: a nationwide survey in Korea. Ann Surg Oncol 2010; 17: 54-64.
23. Kodera Y, Ito S, Yamamura Y, Mochizuki Y, Fujiwara M, Hibi K, Ito K, Akiyama S, Nakao A: Follow-up surveillance for recurrence after curative gastric cancer surgery lacks survival benefit. Ann Surg Oncol 2003; 0: 898-902.
24. Böhner H, Zimmer T, Hopfenmüller W, Berger G, Buhr HJ: Detection and prognosis of recurrent gastric cancer - is routine follow- up after gastrectomy worthwhile? Hepatogastroenterology 2000; 47: 1489-1494.
25. Koizumi W, Akiya T, Sato A, Yamaguchi K, Sakuyama T, Nakayama N, Tanabe S, Higuchi K, Sasaki T, Sekikawa T, Tokyo Cooperative Oncology Group (TCOG GI Group): Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidinebased treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo Cooperative Oncology Group, TCOG GC- 0501 trial. Jpn J Clin Oncol 2009; 39: 713-719.
26. Lim JY, Cho JY, Oh KJ, Choi SH, Lee SI, Jeung HC: Oxaliplatin combined with continuous infusion of 5-fluorouracil as firstline chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma. Chemotherapy 2009; 55: 200-206.
27. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A, Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009; 10: 1063-1609.
28. Cutsem EV, Kang Y, Chung H, Shen L, Sawaki A, Lordick F, Hill J, Lehle M, Feyereislova A, Bang Y: Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 2009; 27(suppl):18.